Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Sanofi’s anti-OX40L antibody, amlitelimab, passed a 390-patient Phase IIb trial by hitting the primary endpoint, with patients seeing up to a 61.5% improvement on a scale used to measure eczema severity, the company said at the European Academy of Dermatology…